Literature DB >> 8500791

Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation.

R J Wise1, B M Ewenstein, J Gorlin, S C Narins, M Jesson, R I Handin.   

Abstract

The differential diagnosis of the genetic bleeding disorders, hemophilia A and von Willebrand disease, is occasionally confounded by the close molecular relationship of coagulation factor VIII and von Willebrand factor (vWF). This report describes the autosomal inheritance of a hemophilia A phenotype due to a mutation of vWF that results in defective factor VIII binding. The proband was a female patient with low levels of factor VIII activity. Polymerase chain reaction (PCR) amplification and DNA sequencing were employed to examine exons encoding the putative factor VIII binding domain of vWF. The patient was found to be homozygous for a single point mutation causing a Thr-->Met substitution at amino acid position 28 in the mature vWF subunit. The phenotypic expression of the mutation was determined to be recessive because heterozygous family members were clinically unaffected. Recombinant vWF containing the observed amino acid substitution was expressed in COS-1 cells. The mutant vWF was processed and secreted normally, and was functionally equivalent to wild-type vWF in its ability to bind to platelets. However, the mutant failed to bind factor VIII, demonstrating that the mutation was functionally related to the observed hemophilia phenotype. The family we describe demonstrates the recessive inheritance of a recently recognized class of genetic bleeding disorders, we call "autosomal hemophilia." We conclude that vWF mutation may be an under recognized cause of hemophilia, especially in cases where the inheritance pattern is not consistent with X-linked transmission.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500791     DOI: 10.1007/BF00217358

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  29 in total

1.  A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction.

Authors:  C Mazurier; J Dieval; S Jorieux; J Delobel; M Goudemand
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

2.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites.

Authors:  H Mohri; A Yoshioka; T S Zimmerman; Z M Ruggeri
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

4.  The "Normandy" variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene.

Authors:  C Gaucher; S Jorieux; B Mercier; D Oufkir; C Mazurier
Journal:  Blood       Date:  1991-05-01       Impact factor: 22.113

5.  Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling.

Authors:  C Mazurier; C Gaucher; S Jorieux; A Parquet-Gernez; M Goudemand
Journal:  Br J Haematol       Date:  1990-11       Impact factor: 6.998

6.  Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.

Authors:  P A Kroner; K D Friedman; S A Fahs; J P Scott; R R Montgomery
Journal:  J Biol Chem       Date:  1991-10-15       Impact factor: 5.157

7.  Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene.

Authors:  I R Peake; D Bowen; P Bignell; M B Liddell; J E Sadler; G Standen; A L Bloom
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

8.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.

Authors:  R J Kaufman; L C Wasley; A J Dorner
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

10.  Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.

Authors:  J A Koedam; J C Meijers; J J Sixma; B N Bouma
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.